Keane's Corner VL

KEYNOTE-057 in High-Risk, Non-Muscle Invasive Bladder Cancer: Trial Highlights by Tom Keane

Details
Tom Keane provides a comprehensive review of phase 2 KEYNOTE-057, assessing treatment with pembrolizumab for high-risk, non-muscle invasive bladder cancer in patients who are unresponsive to Bacillus Calmette (BCG), current standard of care in this patient population. Biography: Thomas E. Keane, MBBCh, FRCSI, FACS Related Content: Pembrolizumab for High-Risk Non–Muscle Invasive Bladder Cancer (NMI...

Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus ADT for Men with Advanced Prostate Cancer - Tom Keane

Details
(Length of video: 9 min) Tom Keane reviews an article entitled, “Comparative Effectiveness of Radical Prostatectomy with Adjuvant Radiotherapy versus Radiotherapy Plus Androgen Deprivation Therapy for Men with Advanced Prostate Cancer”. Men with locally advanced prostate cancer or regionally advanced prostate cancer treated initially with radical prostatectomy plus radiation had a lower risk of pr...

CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane

Details
(Length of Discussion: 30 min) Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018. This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx. He discusses the clinical applica...

Prostate Cancer Highlights from AUA 2018 with Tom Keane

Details
(Lenght of Discussion: 14 min) Tom Keane reviews three key presentations from the most recent American Urological Association (AUA) 2018 meeting. Among the presentations Keane discusses is a prostate cancer Imaging presentation by the Chief of MRI and Nuclear Medicine at the San Francisco VA Medical Center, Thomas Hope, MD. During his presentation, Prostate Cancer: What PET to GET? Hope discussed...

The Changing Landscape in Advanced Bladder Cancer - Tom Keane

Details
(Length of Discussion: 16 min) Dr. Tom Keane discusses the rapidly changing landscape in advanced bladder cancer with the introduction of immune checkpoint inhibitors. To begin his discussion he references a presentation by Thomas Powles, MD from the 2018 ASCO GU meeting where Dr. Powles provided an overview of immune checkpoint inhibitors in urothelial carcinoma at the current time and Dr. Powles...

New Concepts in ADT- Thomas Keane

Details
(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Discussion of an Online Tool to Explore Evolving Practice Patterns in Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...

Discussion of the IMmotion 151 Trial: Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...

Discussion of the CABOSUN trial - Advanced Renal Cell Carcinoma - Thomas Keane

Details
(Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...

Discussion on FALCON: Impact of 18F-fluciclovine PET/CT on Clinical Management Choices for Men with Biochemically Recurrent Prostate Cancer

Details
(Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...